Nurix Therapeutics, Inc. (NRIX)

Over the past six months, Nurix Therapeutics' stock price has been impacted by several events, including a $250.0 million registered offering of common stock in October 2025, the initiation of the DAYBreak™ pivotal study of bexobrutideg in relapsed or refractory chronic lymphocytic leukemia, analyst rating updates in January 2026, and insider stock sales in late January 2026. As of February 4, 2026, the stock price was $16.56 per share, representing a decline of 13.78% from February 5, 2025, but a gain of 71.24% over the past six months.

Nurix Therapeutics, Inc. does not exhibit typical demand seasonality for its products and services, as the demand for its product candidates is driven by the progression of clinical trials, regulatory approvals, and the medical need for treatments in oncology and autoimmune diseases.

Nurix Therapeutics, Inc., founded in 2009, is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small molecule and antibody therapies, leveraging its DNA-encoded library technologies and expertise in E3 ligases to develop targeted protein degradation drugs for cancer, inflammatory conditions, and other diseases. The company's clinical pipeline includes bexobrutideg (NX-5948), an orally bioavailable BTK degrader in Phase 2 trials; zelebrudomide (NX-2127), an orally bioavailable degrader of BTK and IKZF1/3 in Phase 1 trials; NX-1607, an orally bioavailable CBL-B inhibitor in Phase 1 trials; and GS-6791 (NX-0479), an IRAK4 degrader developed with Gilead Sciences. Nurix also has a preclinical pipeline and collaboration agreements with Gilead Sciences, Sanofi S.A., Pfizer Inc., and Bristol Myers Squibb.

Nurix Therapeutics, Inc. has a presence in the United States, with its corporate headquarters in San Francisco, California, serving as the central hub for business operations and strategic planning. The company has research and development centers in Brisbane, California, and The Woodlands, Texas, which are crucial for advancing its discovery and development initiatives.

In the past year, Nurix Therapeutics has maintained a positive brand reputation among analysts, with a consensus rating of "Moderate Buy" and an average rating score of 2.88. The consensus price target is $29.50, representing a significant upside from its current price. Positive clinical trial data for NX-5948, analyst upgrades and price target increases, and strategic collaborations with major pharmaceutical companies have positively affected Nurix Therapeutics' reputation. However, some valuation metrics suggest the company may be overvalued, and its financial health and growth prospects indicate potential to underperform the market.

Nurix Therapeutics, Inc. has a diverse ownership structure, with institutional investors holding approximately 36.75% of the company's stock, insiders owning about 4.87%, and public companies and individual investors holding 58.37%. There are 335 institutional owners and shareholders holding a total of 95,606,195 shares. Major institutional owners include Fmr Llc, BlackRock, Inc., Deep Track Capital, LP, and Vanguard Group Inc.